Krystal Biotech, Inc.

NASDAQ (USD): Krystal Biotech, Inc. (KRYS)

Last Price

159.05

Today's Change

-2.99 (1.84%)

Day's Change

157.86 - 165.78

Trading Volume

206,596

Overview

Market Cap

4 Billion

Shares Outstanding

28 Million

Avg Volume

400,595

Avg Price (50 Days)

160.30

Avg Price (200 Days)

127.99

PE Ratio

407.82

EPS

0.39

Earnings Announcement

06-May-2024

Previous Close

162.04

Open

163.18

Day's Range

157.86 - 165.785

Year Range

82.09 - 189.97

Trading Volume

237,974

Price Change Highlight

1 Day Change

-1.85%

5 Day Change

-2.24%

1 Month Change

-4.93%

3 Month Change

24.06%

6 Month Change

35.88%

Ytd Change

27.28%

1 Year Change

87.12%

3 Year Change

94.44%

5 Year Change

381.09%

10 Year Change

1394.83%

Max Change

1394.83%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment